natgillin/translations-raw huggingface dataset:
in Formula 12 and Formula 13 is as defined above in Formula 3; and 
R!', Ri R* u Formuli 4 i Formuli 5 su definirani kao za Formulu 3; i
The mixture was kept under stirring for 15 minutes and left to cool. 
Smjesa se održava uz miješanje 15 minuta i ostavi da se ohladi.
A conjugate comprising an antibody of claim 1 coupled to a therapeutic agent, preferably a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji sadrži protutijelo sukladno patentnom zahtjevu 1 povezano s terapijskim sredstvom, poželjno toksinom, radioizotopom, lijekom ili citotoksičnim sredstvom.
is selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, and quinoxalin-2-yl, pyrimidin-4-yl, 1,1-dioxotetrahydrothiophen-3-yl and cyclopropyl, wherein R2 is optionally substituted with one or more substituents independently selected from methyl and halogen; or 
je odabran od piridin-2-il, piridin-3-il, piridin-4-il, pirazin-2-il, i kinokslin-2-il, pirimidin-4-il, 1,1-dioksotetrahidrotiofen-3-il i ciklopropil, pri čemu je R2 proizvoljno supstituiran s jednim ili više supstituenata, koji su neovisno odabrani od metila i halogena; ili
The binder can be one of starch, cellulose, polyvinylpyrrolidone, xanthan gum, alginic acid, agar or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 14, naznačena time što se vezivo sastoji od škroba, celuloze, polivinilpirolidona, ksantan gume, alginske kiseline, agara ili kombinacija navedenog.
The compound of Paragraph 14, wherein the compound is represented by the following structural formula: 
Spoj prema zahtjevu 9, pri čemu je spoj prikazan slijedećom strukturnom formulom:
iso-Butyl sidechain acid (Formula 28) was dissolved in 1.0mL DCM then this solution was charged to the reaction flask followed by 6mg (0.038mmol, 0.15 eq.) 
kiseline s izo-butil bočnim lancem (formula 28) bilo je otopljeno u 1.0 ml DCM i tada je ta otopina bila stavljena u tikvicu za reakciju, nakon čega je bilo dodano 6 mg (0.038 mmol, 0.15 ekv.)
Use of a compound according to any of claims 1-10 characterised in that R2-5 are independently selected from the group consisting of hydrogen, halogen, C1-6-alkyl, preferably methyl, C1-6-alkoxy and C1-6-alkoxy-C1-6-alkoxy, preferably 2-methoxy-ethoxy. 
Upotreba spoja, koji je dan bilo kojim patentnim zahtjevima 1-10, naznačena time, da R** su neovisno odabrani iz skupine koja sadrži vodik, halogen, C; 4-alkil, preferirano metil, C;.5-alkoksi i C1.g-alkoksi-C,.g-alkoksi, preferirano 2-metoksi-etoksi.
Typically the additional active compound (c) is selected from the group consisting of (a) B2 agonists and (b) cortiocosteroids. 
Kombinacija sukladno patentnom zahtjevu 9, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) kortikosteroida.
Process according to claim 6, wherein said additional peroxide initiator is selected from the group consisting of compounds having the formula (II), ie OO-t-alkyl-O-alkyl monoperoxycarbonate, wherein t-alkyl contains from 4 to 12 carbon atoms, preferably from 4 to 5 carbon atoms, and alkyl contains from 3 to 12 carbon atoms, and preferably 8 carbon atoms, and their mixtures. 
Postupak prema zahtjevu 6, naznačen time da navedeni dodatni peroksidni inicijator je odabran iz skupine koja se sastoji od spojeva koji imaju formulu (11%), odnosno OO-t-alkil-O-alkil monoperoksikarbonat, pri čemu t-alkil sadrži od 4 do 12 atoma ugljika, poželjno od 4 do 5 atoma ugljika, a alkil sadrži od 3 do 12 atoma ugljika, te poželjno 8 atoma ugljika, i njihove mješavine.
the Fmoc group R5 is cleaved with a solution of piperidine or 4-methyl-piperidine in a suitable organic solvent; 
Fmoc skupina R5 se razgrađuje otopinom piperidina ili 4-metil-piperidina u prikladnom organskom otapalu;
The pharmaceutical composition of claim 1, wherein said corticosteroid is selected from the group consisting of budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone, and salts, solvates, esters, and mixtures thereof. 
Farmaceutski pripravak prema patentnim zahtjevima 1, 2, 3, ili 4, naznačen time što je navedeni kortikosteroid odabran iz grupe koja se sastoji od budesonida, flutikazona, flunizolida, ciklesonida, mometazona, beklometazona, i soli, solvata, estera, i njihovih smjesa.
The compound or composition for use of claim 4, wherein the Syk-mediated disease is allergic asthma, allergic rhinitis, rheumatoid arthritis, multiple sclerosis, lupus, systemic lupus erythematosus, lymphoma, B cell lymphoma, T cell lymphoma, leukemia, myelodysplasic syndrome, anemia, leucopenia, neutropenia, thrombocytopenia, granuloctopenia, pancytoia or idiopathic thrombocytopenic purpura. 
Spoj ili sastav prema zahtjevu 4, naznačen time, da se kod Syk-posredovane bolesti radi o sljedećoj bolesti: alergijska astma, alergijski rinitis, reumatoidni artritis, multipla skleroza, lupus, sustavna lupus eritematoza, limfom, limfom B-stanice, limfom T-stanice, leukemija, mijelodisplazijski sindrom, anemija, leukopenija, neutropenija, trombocitopenija, granulocitopenija, pancitoja ili idiopatska trombocitopenijska purpura.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method according to any of embodiments 9-16, wherein the therapeutically effective amount of acetyl-leucine is from about 1 g to about 15 g per day, from about 1 g to about 10 g per day, from about 1.5 g to about 7 g per day, from about 4 g to about 6 g per day, or from about 4 g to about 5 g per day. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-11, pri čemu postupak sadrži primjenu acetil-leucina na subjektu kojemu je to potrebno u terapeutski djelotvornoj količini od oko 1 g do oko 15 g dnevno, od oko 1 g do oko 10 g dnevno, od oko 1,5 g do oko 7 g dnevno, od oko 4 g do oko 6 g dnevno, ili od oko 4 g do oko 5 g dnevno.
A compound, salt or composition according to claim 6 wherein the neoplastic disease is selected from lung cancer, head and neck cancer, central nervous system cancer, prostate cancer, testicular cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, biliary tract cancer, esophageal cancer, gastrointestinal stromal tumor, breast cancer, cervical cancer, ovarian cancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma, basal cell carcinoma, squamous cell carcinoma, bladder cancer, renal cancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome and myeloproliferative disease. 
Spoj, sol ili kompozicija, prema Zahtjevu 6, naznačeni time, što se spomenuta neoplastična bolest bira između slijedećih: kancer pluća, kancer glave 1 vrata, kancer središnjeg živčanog sustava, kancer prostate, kancer testisa, HR P20150778 T1 kolorektalni kancer, kancer pankreasa, kancer jetre, kancer želuca, kancer žučnog trakta, kancer jednjaka, gastrointestijalni stromalni tumor, kancer dojke, kancer cerviksa, kancer jajnika, kancer uterusa, leukemija, limfomi, multipli mijelom, melanom, karcinom bazalnih stanica, karcinom skvamoznih stanica, kancer mjehura, kancer bubrega, sarkom, mezotelioma, timom, mijelodisplastični sindrom i mijeloproliferativna bolest.
a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from the group consisting of: 
3-člana do 8-člana monociklička nearomatska heterociklička skupina opcionalno supstituirana s 1 do 3 supstituenta odabrana od: atoma halogena,
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Farmaceutski oblik za doziranje s produljenim otpuštanjem u krutom obliku za oralnu upotrebu prema zahtjevu 1, naznačen time da je aktivni agens oksikodon hidroklorid i gdje oblik za doziranje kada je testiran u usporednoj kliničkoj studiji je bioekvivalentan komercijalnom proizvodu OxyContinTM.
The compound of claim 9 for use in treating hepatitis C infections further comprising using at least one additional compound having therapeutic benefits for HCV wherein the compound is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors. 
. Smjesa prema zahtjevu 9, naznačena time što se koristi za liječenje zaraza virusom hepatitisa C i dalje sadrži barem jedan dodatni spoj s terapijskim učinkom na HCV pri čemu se taj spoj izabire iz skupine koja obuhvaća interferone, ciklosporine, interleukine, inhibitore metaloproteaze HCV-a, inhibitore serin proteaze HCV-a, inhibitore polimeraze HCV-a, inhibitore helikaze HCV-a, inhibitore proteina NS4B HCYV-a, inhibitore ulaska HCV-a, inhibitore nakupljanja HCV-a, inhibitore izlaska HCV-a, inhibitore proteina NS5A HCV-a, inhibitore proteina NS5B HCV-ai inhibitore replikacije HCV-a
A packaging according to claim 16, wherein the signal emitting means is adapted to emit electromagnetic signals and/or magnetic fields. 
Pakiranje u skladu s patentnim zahtjevom 16, naznačeno time, što je sredstvo koje emitira signal prilagođeno da emitira elektromagnetske signale i/ili magnetska polja.
The solid pharmaceutical dosage form may optionally contain an effective amount of a non-hygroscopic bulking agent. 
Čvrsti dozirni oblik prema zahtjevu 1, naznačen time, da nadalje sadrži učinkovitu količinu nehigroskopnog sredstva za povećanje obujma.
copolymers of ethylene with at least one ester having an ethylene unsaturation selected from the group consisting of: C1-C8 alkyl acrylate, C1-C8 alkyl methacrylates, or vinyl C2-C8 carboxylates; and 
kopolimera etilena sa najmanje jednim esterom koji ima etilensko nezasićenje izabrano od: C1-C8 alkil akrilata, C1-C8 alkil metakrilata i vinil C2-C8 karboksilata;
represents alkylaryl, carboxy, alkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkenyl, carbamoyl, hydroxyalkyl, aryloxy, alkoxycarbonyloxy, alkoxycarbonyl, alkoxy, alkoxyalkyl, aryl, a heterocyclic ring, aminocarbonyl, alkylthio, alkylcarbonylamino, hydroxy, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, or amino, all of which are optionally substituted by one or more, same or different substituents selected from R7; 
predstavlja alkilaril, karboksi, alkil, alkenil, cikloalkenil, alkinil, haloalkil, cikloalkil, cikloalkenil, karbamoil, hidroksialkil, ariloksi, alkoksikarboniloksi, alkoksikarbonil, alkoksi, alkoksialkil, aril, heterociklični prsten, aminokarbonil, alkiltio, alkilkarbonilamino, hidroksi, alkilkarbonil, arilkarbonil, alkilkarboniloksi ili amino, gdje su svi oni izborno supsitituirani sa jednim ili više, istih ili različitih supstituenata izabranih od R7;
wherein said polymerizable resin base, upon polymerization and in the absence of any compensating effect from the at least one filler ingredient, causes a volumetric shrinkage (AV resin) of the composite material of at least 0.50%, and wherein said composite material, upon polymerization of said polymerizable resin base and upon phase transformation of said at least one filler ingredient, exhibits a total volumetric shrinkage (AVtotal) of at least 0.25%-point less than an uncompensated volumetric shrinkage (AVresin) caused by the polymerizable resin base. 
Kompozitni materijal prema patentnom zahtjevu 1, naznačen time da je rečena baza za smolu nakon polimerizacije, a u odsutnosti bilo kojeg kompenzirajućeg efekta od jednog ili više materijala za punjenje, uzrokuje volumetrijsko skupljanje (AV) kompozitnog materijala najmanje 0.50%, a rečeni kompozitni materijal nakon polimerizacije rečene baze za smolu i nakon fazne transformacije rečenog sastojka(aka) za punjenje pokazuje ukupno voiumetrijsko skupljanje (AVukupno) najmanje 0.25 %-poena manje od nekompenziranog velumetrijskog skupljanja (AVamote) Uzrokovanu bazom za smolu.
A process for producing a pharmaceutical composition according to any one of claims 8 to 11, said process comprising admixing said polypeptide or polynucleotide sequence with a pharmaceutically acceptable excipient, carrier or diluent; optionally said polypeptide or polynucleotide sequence is encapsulated in said process; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5. 
Postupak za proizvodnju farmaceutskog pripravka prema bilo kojem od zahtjeva 8 do 11, te navedeni postupak sadrži miješanje navedenog polipeptida ili polinukleotidne sekvence s farmaceutski prihvatljivim pomoćnim sredstvom, nosačem ili razrjeđivačem; proizvoljno navedeni polipeptid ili polinukleotidna sekvenca je inkapsulirana u navedenom postupku; pri čemu je navedeni polipeptid najmanje 75% identičan sa SEQ ID NO 2, SEQ ID NO 4 ili SEQ ID NO 6 i pri čemu navedena polinukleotidna sekvenca kodira navedeni polipeptid koji je najmanje 75% identičan sa SEQ ID NO 2, SEQ ID NO 4 ili SEQ ID NO 6 i/ili pri čemu navedena polinukleotidna sekvenca je najmanje 75% identična sa SEQ ID NO 1, SEQ ID NO 3 ili SEQ ID NO 5.
The drain assembly according to claim 1, wherein the distance between the first planar surface and the second planar surface is less than 20 mm. 
Sifon za mirise (100) sukladno bilo kojem od prethodnih zahtjeva, naznačen time da je udaljenost između prve ravne površine 1 druge ravne površine manja od 20 mm.
A represented procedure was reported by Bas, M.-D. and co-workers in J Labeled Compd Radiopharm. 
Prikazani postupak je objavljen od Bas, M-D. i sur.
a bad prognosis, the need for additional cancer treatment for the subject, to select the cancer subject for additional cancer treatment, or 
lošu prognozu, (di) potrebu za dodatnim liječenjem raka kod subjekta, (ili) = odabir subjekta sa rakom za dodatno liječenje raka, ili (iv) - dajerak metastatski.
a step of mixing a pesticide active ingredient, an amine being capable of forming an associated state with the pesticide active ingredient and containing a group having a hydrophobic moiety on a nitrogen atom, a heat-meltable material and/or a thermoplastic material, and a carrier under heating. 
- = korak miješanja, uz zagrijavanje, aktivnog sastojka pesticida, amin koji je sposoban tvoriti povezano stanje s aktivnim sastojkom pesticida 1 koji sadrži skupinu koja ima hidrofobnu skupinu na dušikovom atomu,
In a preferred embodiment, said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, preferably of from 1000 to 5000 mg, and more preferably of 1 300 to 2000 mg, per liter of the aqueous phase of said suspension. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu otopinu u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene otopine.
A 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to claims 1-10 for use in therapy. 
Derivat 4-fcnil-5-okso-1,4,5,6,7,8-heksahidrokinolina u skladu s patentnim zahtjevima 1-10, namijenjen upotrebi u terapiji. patentnih zahtjeva 1-10 1 farmaceutski prihvatljive pomoćne tvari.
In one subgroup of compounds according to the invention, E represents substituted or unsubstituted 5- or 6-membered heteroaryl such as a nitrogen-containing heteroaromatic group, for example, uracil. 
U jednoj podskupini spojeva prema ovom izumu E predstavlja supstituirani ili nesupstituirani 5- ili 6- člani heteroaril, poput heteroaromatske skupine koja sadrži dušik, primjerice uracil.
Aclidinium for use in improving the quality of sleep in respiratory patients 
AKLIDINIJ ZA PRIMJENU U POBOLJŠANJU KVALITETE SNA KOD RESPIRATORNIH BOLESNIKA
An alternative embodiment of the invention relates to a bispecific single chain antibody comprising a first domain binding domain capable of binding to CD3 epsilon (CD3e) of human and non-chimpanzee primate and a second domain binding domain capable of binding to the extracellular domain of the mutated human PSMA having an amino acid sequence as depicted in SEQ ID NO: 447 but not to the extracellular domain of the rodent PSMA. 
(a) vežuća domena, koja se može vezati na izvanstaničnu domenu mutiranog ljudskog PSMA s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 447, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 7171721 mutirani u odgovarajuće aminokiselinske ostatke PSMA divljeg tipa glodavca, no ne i na izvanstaničnu domenu PSMA glodavca;
coupling a compound of formula 8: with a compound of formula 9: in the presence of a coupling reagent to yield the compound of formula 10: 
(a) spajanja spoja formule 8: (D, u nazočnosti reagensa za spajanje kako bi se dobio spoj formule 10: ze
The sulfide compounds may also be prepared as follows: an (optionally protected) cysteine is alkylated with an appropriate Z—CH2— group, and the tripeptide or tetrapeptide then formed by standard methods of peptide synthesis, coupling first with an amino acid of the formula 
(po izboru zaštićeni) cistein alkiliran je sa prikladnom Z-CH,- skupinom, i standardnim postupcima sinteza peptida formirani su tripcptid ili tetrapcptid, prvo spajanjem sa amino kiselinom formulc Y HN" "GOGH
said alert method comprises: closing the electric valve “A” and transmitting a “break” alert over the system network before ending the method; 
• korake (13-8, 13-9) za zatvaranje električnog ventila A i slanje upozorenja o zatajenju u mreži sustava prije završavanja postupka;
About 1% w/w of CSGS 10A were mixed in the above mentioned PU-acrylate dispersion and the conductive flooring were coated with approx 20 g/m2 in a roller coating station. 
Oko 1 % težinskog udjela CSGS 10A pomiješa se u gore navedenu PU-akrilnu disperziju i vodljiva podna obloga se premaze s približno 20 g/m2 u pogonu za nanošenje valjcima.
each of R5 and R6, which are the same or different, is a hydrogen atom, a halogen atom, a C1-3 alkyl group which may have a halogen atom as a substituent or C1-3 alkoxy group. 
R'iR* koji mogu biti identični ili različiti jedan od drugog, predstavljaju atom vodika, atom halogena, C;.g alkil skupinu, koja može imati atom halogena kao supstituent, ili C1-3 alkil skupinu ili njihovu sol.
The method of claim 1, wherein the disease is chronic obstructive pulmonary disorder. 
Spoj za uporabu prema zahtjevu 11, naznačen time što je bolest kronična opstruktivna bolest pluća.
Desirably, before being introduced into the forming mandrel 13, the process air flowing out of the forming chamber 1 is subjected to a post-treatment step which comprises at least one relative cooling sub-step. 
Postupak oblikovanja prema zahtjevu 15, naznačen time da prije nego što se uvodi u rog za oblikovanje (13), zrak za postupak koji istječe iz komore za oblikovanje (1) se podvrgava naknadnom-koraku obrade koji sadrže najmanje jedan pod-korak hlađenja.
a fusion protein comprising the human membrane proximal 640 amino acid residues identified in step (a) and the rodent amino acid residues >640 of c-MET, TEM1 or IGF-1R; and 
(1) fuzijski protein koji sadrži ljudske membranske proksimalne 640 aminokiselinskih ostataka identificiranih u koraku (a) i glodavačke aminokiselinske ostatke >640 u c-MET, TEMI ili IGF-IR; i
The nucleic acid of clause 34, wherein said optimized viral polypeptide comprises any one of the amino acid sequences set forth in SEQ ID NOS:1-29. 
Cjepivo prema zahtjevu 4, gdje spomenuto cjepivo sadrži jedan ili više vektora koji kodiraju: barem dva različita optimizirana gag polipeptida koji sadrže sekvence amino kiselina prikazane u SEQ ID NOs:
In such situations then, said wood preferably is so-called green lumber, that is, wood from freshly cut trees that either was stored not at all or, in comparison, was optionally stored only for a short time. 
U takvim okolnostima je poželjno da se tada kao navedeno drvo koriste tako zvane zelena debla, to jest, drvo od svježe odrezanog drveća koje uopće nije bilo uskladišteno ili je po potrebi bilo uskladišteno samo na kratko vrijeme.
The method of claim 1, wherein the bags (20) are of overall generally rectangular shape, and step (c) takes place by sealing together the joined edges of the part-formed bag along three sides of the generally rectangular bag. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da su vrećice (20) općenito pravokutnog oblika, a korak (c) izvršava se hermetičkim spajanjem postavljenih rubova djelomično oblikovane vrećice duž triju stranica pravokutne vrećice.
a composition comprising a therapeutically effective amount of at least one first agent chosen from 2-acetylnaphtho[2,3-b]furan-4,9-dione and pharmaceutically acceptable solvates thereof, 
Kombinacija iz patentnog zahtjeva 1, pri čemu je prvi agens 2-acetilnafto[2,3-b]furan-4,9-dion ili njegova farmaceutski prihvatljiva sol ili solvat.
A safety bow according to claim 1 or 2, wherein the safety bow is depth and/or height adjustable in relation to the backrest and the possible two side pieces, in adaption to a depth and/or height adjustable seat plate (2). 
odnosu na naslon za leđa i moguća dva bočna elementa, za podešavanje dubine i/ili visine podesive ploče za sjedenje (2).
The latter structure of the base unit adapted for cooperation with the base part, allows the container unit consisting of the container and the base unit to stand upright with the outlet of the container facing downwards. 
Potonja struktura osnovne jedinice, prilagođena tako da djeluje zajedno s osnovnim dijelom, omogućuje da jedinica spremnika, koja se sastoji od spremnika i osnovne jedinice stoji uspravno s izlazom iz spremnika okrenutim prema dolje.
a piercing thorn, the thorn protruding centrally and perpendicularly from the housing. The assembly of claim 23, wherein said predetermined position comprises the thorn of the withdrawal spike being inserted through the vial cap by a predetermined distance. 
Sklop prema patentnom zahtjevu 23, naznačen time, da navedeni predodređeni položaj sadrži trn (32) ekstrakcijskog šiljka (30) koji je uveden kroz kapicu (24) bočice za predodređenu duljinu.
adding a sugar, an amino acid and a detergent to the solution, 
dodavanje šećera i deterdženta u otopinu,
Preferred examples of a group of the formula: 
Datum podnošenja europske prijave patenta:
a rhesus CMV (RhCMV) vector that encodes a heterologous antigen and functional Rh182-Rh185 proteins and does not express an active Rh189 protein; and wherein the heterologous antigen is an infectious disease antigen or a tumor antigen. 
rezusni vektor CMV (RhCMV), koji kodira heterologni antigen i funkcionalne proteine Rh182-Rh185, a ne eksprimira aktivni protein Rh189; i naznačen time što je heterologni antigen antigen povezan sa zaraznom bolešću ili tumorski antigen.
or a pharmaceutically acceptable salt thereof. Embodiment 31 A composition comprising a compound of any one of embodiments 1-30, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
Pripravak naznačen time što sadrži jedan ili više spojeva iz bilo kojeg od zahtjeva 1-14, ili jednu ili više njihovih farmaceutski prihvatljivih soli, te jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
In one preferred embodiment, the method is applied to prevent, reduce or treat an unforeseen, sudden or acute occurrence of ischemic reperfusion. 
Upotreba u skladu s patentnim zahtjevom 12, naznačena time što do neočekivano iznenadne ili akutne pojava ishemije i reperfuzijske ozljede dolazi nakon inzulta ili perinatalnog inzulta.
a flange connected to the body, 
Prirubnicu (21) koje su spojene na trup
In one embodiment, R1 represents cyclopropyl. 
Spoj u skladu sa zahtjevom 2, naznačen time, da R' predstavlja ciklopropil.